Physician profile
Erin E Thomas
NPI 1780919696
$9,602.86
in general payments reported to CMS, 2019-2025
55 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,592 · 2022: $2,130 · 2023: $2,268 · 2024: $1,274 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,494 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.96 |
| Education | $386.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,010.10 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $788.74 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $758.69 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $741.43 | 2022-2025 | Dupixent, Libtayo, Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $620.63 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Genzyme Corporation | $582.89 | 2022-2025 | |
| Csl Behring | $578.74 | 2022-2025 | Haegarda, Hizentra |
| Novo Nordisk INC | $452.19 | 2021-2022 | |
| Genentech USA, INC. | $417.99 | 2023-2025 | Xolair, Itovebi, Venclexta |
| Kaleo, INC. | $321.36 | 2022-2024 | Auvi-Q |
| Abbvie INC. | $290.19 | 2021-2025 | |
| Lilly USA, LLC | $248.80 | 2021-2025 | Verzenio, Jaypirca |
| Insulet Corporation | $222.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $210.40 | 2021-2024 | |
| Janssen Biotech, INC. | $187.75 | 2025 | Darzalex, Talvey, Tecvayli |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.